

Steve Sisolak
Governor
Richard Whitley, MS
Director



**DEPARTMENT OF
HEALTH AND HUMAN SERVICES**
Division of Health Care Financing and Policy
Helping people. It's who we are and what we do.



Suzanne Bierman, JD, MPH
Administrator

Silver State Script Board

Draft Meeting Minutes

Date of Meeting: Thursday, January 21, 2021

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Silver State Script Board

Agenda Item	Record		Notes	
Closed Executive Session		Present	Absent	The DHCFP Staff Present were as follows: Gudino-Vargas, Antonio, Social Services Program Specialist III Flowers, Ellen, Program Officer I Lithier, Gabriel, DAG Olsen, David, Social Services Chief III Young, DuAne, Deputy Administrator
	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
	Hautekeet, Mike, R.Ph	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
	Passalacqua, Brian, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Singh, Aditi, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>		

Agenda Item	Record	Notes																														
		<p>DXC Staff Present were as follows: Leid, Jovanna, Pharm.D.</p> <p>OptumRx Staff Present were as follows: Whittington, Kevin, R.Ph Jeffery, Carl, Pharm.D. Chien, Michael, Pharm.D. Piccirilli, Annette</p>																														
<p>1. Call to Order and Roll Call</p>	<p>Chairman Decerbo called the meeting to order at 1:42 p.m. on January 21, 2021</p> <p>The roll was taken by Chairman Decerbo.</p> <table border="0" data-bbox="598 787 1344 1193"> <thead> <tr> <th></th> <th>Present</th> <th>Absent</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Passalacqua, Brian, MD</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> <p>A quorum was present.</p>		Present	Absent	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Passalacqua, Brian, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Singh, Aditi, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<p>The DHCFP Staff Present were as follows: Gudino-Vargas, Antonio, Social Services Program Specialist III Flowers, Ellen, Program Officer I Lither, Gabriel, DAG Olsen, David, Social Services Chief III Young, DuAne, Deputy Administrator</p> <p>DXC Staff Present were as follows: Leid, Jovanna, Pharm.D.</p> <p>OptumRx Staff Present were as follows: Whittington, Kevin, R.Ph Jeffery, Carl, Pharm.D.</p>
	Present	Absent																														
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Hautekeet, Mike, R.Ph	<input type="checkbox"/>	<input checked="" type="checkbox"/>																														
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Passalacqua, Brian, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																														
Singh, Aditi, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																														
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														

Agenda Item	Record	Notes
		<p>Chien, Michael, Pharm.D. Piccirilli, Annette</p> <p>The public attendee list is included as Attachment A.</p> <p>Note: Participants may not have chosen to reveal their identity and in the absence of a sign-in sheet the accuracy of the attendee list is not assured.</p>
<p>2. Public Comment on Any Matter on the Agenda</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p>	
<p>3. Administrative</p>		

Agenda Item	Record	Notes																												
<p>a. For Possible Action: Review and Approve Meeting Minutes from September 24, 2020</p>	<p>No corrections were offered.</p> <p>Board Member Adashek moved to approve the minutes as presented.</p> <p>Board Member Khurana seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0" data-bbox="598 479 1501 760"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
<p>b. Status Update by the DHCFP</p>	<p>Antonio Gudino-Vargas updated the Board regarding the updated COVID-19 billing guides specific to community-based testing and includes information on administering COVID vaccines.</p> <p>Deputy Young updated the Board on promoting Antonio Gudino-Vargas to the Program Manager position within the DHCFP and plans regarding backfilling his previous position. Deputy Young also announced the Chief position had been filled, and they will start on February 1, 2021. Deputy Young referenced the legislative session’s start on February 1, 2021 and discussed the budget concerns due to COVID-19. He added that he is hopeful the F-MAP that has been extended to June 30, 2021, means some previous rate cuts can be restored before anticipated. Deputy Young updated the Board on the AB-3 from the 31st Special Session and the requirement for a Specialty Pharmacy Program that is nearing implementation but has been postponed to hear all stakeholders’ concerns.</p>																													

Agenda Item	Record	Notes
	Deputy Young remarked that there are challenges for Medicaid during the Legislative Session due to the 20% growth in caseload but is optimistic Federal Support will be renewed, and Nevada's economy will recover.	
4. Established Drug Classes Being Reviewed Due to the Release of New Drugs		
a. For Possible Action: Discussion and possible adoption of Biologic Response Modifiers, Multiple Sclerosis Agents, Injectable		
i. Public comment	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>A comment was made by Melissa Sommers with Novartis indicating support for Kesimpta. Ms. Sommers highlighted the approved indications and asked Kesimpta to be added as preferred. Ms. Summers detailed the mechanism of action. The administration is at home and pointed to the lack of treatment guidelines. Ms. Sommers highlighted the clinical data demonstrating Kesimpta is shown safe and effective, resulting in significant improvements compared to teriflunomide while being well-tolerated and similar adverse events as teriflunomide. Ms. Sommers reiterated the request for Kesimpta to be preferred on the Nevada Medicaid Preferred Drug List.</p> <p>No further public comment was offered.</p>	
ii. Drug class review presentation by OptumRx.	Dr. Jeffery detailed the indications, mechanism of action, route of administration of Kesimpta. Dr. Jeffery highlighted that Kesimpta is self-administered and described the clinical trial data demonstrating Kesimpta is safe and effective and shown to be superior to teriflunomide. Dr. Jeffery	

Agenda Item	Record	Notes																												
	<p>continued detailing the other medications' indications in the class including Lemtrada, Ocrevus, and Tysabri. Dr. Jeffery reminded the Board of the prior authorization criteria for all medications within the class.</p> <p>Dr. Jeffery displayed the list of medications in the class and recommended the Board consider the class clinically and therapeutically equivalent.</p>																													
<p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p>	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent and Board Member Crumby seconded. A vote was held:</p> <table border="0" data-bbox="604 592 1493 873"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
<p>iv. Presentation of recommendations for PDL inclusion by OptumRx.</p>	<p>Dr. Jeffery outlined the proposed changes to the Injectable Multiple Sclerosis class, adding the new product, Kesimpta, as non-preferred and moving Extavia and Ocrevus to non-preferred, and keeping the rest of the class the same.</p>																													
<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Chairman Decerbo voiced the change with moving Extavia is acceptable but was concerned with moving Ocrevus to non-preferred due to a unique indication of primary progressive MS and asked Dr. Jeffery if there are any prior authorization criteria for Ocrevus.</p> <p>Dr. Jeffery stated there are criteria for both relapsing forms of MS and primary progressive forms of MS.</p> <p>Board Member Ward asked how moving Ocrevus to non-preferred would impact the prior authorization criteria.</p>																													

Agenda Item	Record	Notes																												
	<p>Dr. Jeffery replied the change would apply to the relapsing forms of MS, primary progressive MS in a unique indication for Ocrevus so a member would not have to try a preferred medication in the class prior to starting Ocrevus since none of the preferred medications are indicated for relapsing forms of MS.</p> <p>Chairman Decerbo asked if members established on Ocrevus would have to switch or be grandfathered into their current treatment.</p> <p>Dr. Jeffery recommended grandfathering members be established on Ocrevus to allow their therapy to continue.</p> <p>Board Member Chu moved to accept the list as presented and allow established members to continue Ocrevus therapy, and Board Member Adashek seconded. A vote was held:</p> <table border="0" data-bbox="598 771 1449 1047"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
<p>b. For Possible Action: Discussion and possible adoption of Neurological Agents, Anticonvulsants.</p>																														
<p>i. Public comment</p>	<p>The following written public comment is attached hereto:</p> <ol style="list-style-type: none"> 1) An undated outline of testimony from UCB in support of Briviact. 2) Letter dated December 9, 2020, from Dr. Stephanie Kennedy, Health Outcomes Liaison Manager with Greenwich Biosciences advocating for continued access to Epidiolex. 																													

Agenda Item	Record	Notes
	<p>3) An undated pamphlet from Zogenix highlighting Fintepla clinical data.</p> <p>4) Article from JAMA Neurology, Fenfluramine for Treatment-Resistant Seizures in Patients with Dravet syndrome Receiving Stiripentol-Inclusive Regimens, Published online December 2, 2019.</p> <p>5) Article from The Lancet, Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomized, double-blind, placebo-controlled trial, published online December 17, 2019.</p> <p>6) An undated information sheet from an unknown source for Fintepla.</p> <p>7) Article from Epilepsia, Cardiovascular safety of fenfluramine in the treatment of Dravet Syndrome: analysis of an ongoing long-term open-label safety extension study, published December 3, 2018.</p> <p>8) An undated information sheet from an unknown source for Fintepla.</p> <p>9) Package Insert for Fintepla.</p> <p>The public comment referenced above was highlighted on the record for members of the Board by Dr. Jeffery.</p> <p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was made by Derek Ems, the epilepsy outcomes partner for UCB advocating for Briviact. Mr. Ems highlighted the prevalence of epilepsy, costs associated, and treatment difficulty with treatment-refractory epilepsy. Mr. Ems promoted Briviact as not requiring a gradual dose escalation, outlined the indication, highlighted the mechanism of action and advantages with faster action and superiority over placebo. Mr. Ems asked to keep open access to antiepileptic medications.</p>	

Agenda Item	Record	Notes
	<p>Comment was made by Dr. Maninder Malik, medical science liaison with SK Life Science, advocating for Xcopri. Dr. Malik outlined the unmet need for patients with uncontrolled epilepsy and highlighted the clinical trials with treatment-refractory patients reducing the number of seizures. Dr. Malik requested the Board add Xcopri as preferred.</p> <p>Comment was made by Rod Hamson with the Epilepsy Foundation of Nevada asking for open access for all anti-seizure medications on the Medicaid Preferred Drug List. Mr. Hamson stated the medications are not interchangeable and are individualized and limiting access can lead to harmful changes to the patient's outcomes. Mr. Hamson asked for continued access to all epilepsy medications.</p> <p>No further public comment was offered.</p>	
<p>ii. Drug class review presentation by OptumRx.</p>	<p>Dr. Jeffery highlighted Fintepla's indications and clinical trials demonstrating Fintepla is safe and effective. Dr. Jeffery highlighted the indications for some of the medications proposed to move to non-preferred. Dr. Jeffery informed the Board that Fintepla would be discussed at the DUR Board to add criteria.</p> <p>Dr. Jeffery displayed the list of medications in the class and recommended the Board consider the class clinically and therapeutically equivalent.</p>	
<p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p>	<p>Board Member Khurana asked if the patients on the medications moving to non-preferred would be grandfathered in to allow them to continue.</p> <p>Chairman Decerbo replied, stating it is up to the Board to make that determination.</p> <p>Dr. Jeffery confirmed grandfathering would be up to the Board and reminded the Board two preferred medications are required before getting a non-preferred.</p>	

Agenda Item	Record	Notes																												
	<p>Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent, Board Member Khurana seconded. A vote was held:</p> <table data-bbox="590 378 1514 662"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
iv. Presentation of recommendations for PDL inclusion by OptumRx.	Dr. Jeffery recommended the board add the new agent Fintepla as non-preferred and add Aptiom, Banzel, Briviact, Keppra XR, Keppra, and Sabril as non-preferred moving from preferred.																													

Agenda Item	Record	Notes																												
<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Board Member Khurana moved to accept the preferred list as presented except to grandfather the current patients on these agents and for Fintepla to be preferred for Dravet Syndrome.</p> <p>Chairman Decerbo asked Board Member Khurana to split that into two motions for tracking and make the Fintepla a new motion making the new motion to accept all changes proposed except for Fintepla and grandfather current members on the medications moving to non-preferred.</p> <p>Board Member Khurana confirmed the restated motion. Board Member Adashek seconded the motion. A vote was held:</p> <table border="0" data-bbox="590 662 1514 943"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crummy, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> <p>Board Member Khurana moved to make Fintepla preferred for members with a diagnosis of Dravet Syndrome. Board Member Adashek seconded the motion.</p> <p>Chairman Decerbo asked how this will be listed on the preferred drug list and does it make much difference after the DUR Board adds criteria.</p> <p>Dr. Jeffery proposed adding Fintepla as preferred with an asterisk to indicate it is preferred for Dravet.</p> <p>Board Member Adashek asked about creating a new class for Dravet Syndrome.</p>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crummy, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crummy, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											

Agenda Item	Record	Notes																												
	<p>Chairman Decerbo stated that may add complexity since medications like Epidiolex have other indications.</p> <p>Board Member Khurana updated the motion to make Fintepla preferred and Board Member Adashek seconded. A vote was held:</p> <table data-bbox="604 483 1451 764"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
<p>c. For Possible Action: Discussion and possible adoption of Respiratory Agents, Long-acting/Maintenance Therapy.</p>																														
<p>i. Public comment</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p>																													
<p>ii. Drug class review presentation by OptumRx.</p>	<p>Dr. Jeffery briefly highlighted Breztri, a three-ingredient medication for the treatment of COPD, including the clinical trials demonstrating the medication is safe and effective. Dr. Jeffery informed the Board there could be some other generics coming soon, but nothing has changed recently.</p>																													

Agenda Item	Record	Notes																												
	Dr. Jeffery displayed the list of medications in the class and recommended the Board consider the class clinically and therapeutically equivalent.																													
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Board Member Adashek moved to accept the list as clinically and therapeutically equivalent. Board Member Chu seconded. A vote was held: <table border="0" data-bbox="604 451 1493 735"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
iv. Presentation of recommendations for PDL inclusion by OptumRx.	Dr. Jeffery recommended the Board add the new medication, Breztri, as non-preferred and move Arnuity Ellipta and QVAR Redihaler to non-preferred from preferred.																													
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Chairman Decerbo moved to accept the list as presented, Board Member Adashek seconded. A vote was held: <table border="0" data-bbox="604 998 1493 1281"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
5. Established Drug Classes																														
a. For Possible Action: Discussion and possible adoption of																														

Agenda Item	Record	Notes
Neurological Agents, Anti-Migraine Agents, Calcitonin Gene- Related Peptide (CGRP) Receptor Antagonists		
i. Public comment	<p>The following written public comment is attached hereto:</p> <ol style="list-style-type: none"> 1) An undated Clinical Fact Sheet for Aimovig. 2) Letter dated December 2, 2020, from Maria Agapova in support of Ajovy. 3) An undated Medical Value Summary for Emgality. 4) Letter dated November 18, 2020, from Lydia Borja Estanislao, MD advocating for Nurtec ODT to be preferred. 5) Letter dated November 24, 2020, from Rachael Gardner advocating for Nurtec ODT to be preferred. 6) An undated letter from Quang Nguyen, DO advocating for Nurtec ODT to be preferred. 7) Letter dated November 17, 2020, from Danny Thai advocating for Nurtec ODT to be preferred. 8) Letter dated January 20, 21 from Paul Janda, DO advocating for Ubrelvy to be preferred. 9) Letter dated December 4, 2020, from Lawrence Smith advocating for Ubrelvy to be preferred. 10) Letter dated December 10, 2020, from Denis Patterson, DO advocating for Ubrelvy to be preferred. 11) Letter dated December 8, 2020, from Mouchir Harb, MD advocating for Ubrelvy to be preferred. 12) Letter dated December 8, 2020, from Sidharth Sharma, MD advocating for Ubrelvy to be preferred. <p>The public comment referenced above was highlighted on the record for members of the Board by Dr. Jeffery.</p>	

Agenda Item	Record	Notes
	<p data-bbox="596 233 1444 298">Telephonic and web comment was called for, and the phone lines were opened.</p> <p data-bbox="596 342 1497 656">Comment was offered by Chelsea Leroue with Biohaven Pharmaceuticals providing information on Nurtec ODT. Ms. Leroue pointed out the two preferred medications in the CGRP class are for preventative treatment and neither acute treatment medication is listed as preferred. Ms. Leroue highlighted four differentiators of Nurtec ODT from other acute migraine treatments, including ease of use being one dose and one form, favorable safety profile, sustained efficacy after one dose, and the restoration of the patient’s normal function. Ms. Leroue restated the safety and efficacy and asked the Board to make Nurtec ODT preferred.</p> <p data-bbox="596 699 1497 938">Comment was offered by Ben Droese with Amgen Medical Affairs providing information on Aimovig. Mr. Droese highlighted the mechanism of action, the indication of Aimovig, dosing, safety, and efficacy including the updated data for high blood pressure and dosing in pregnancy, long-term safety and efficacy information demonstrating significant improvement over baseline. Mr. Droese outlined the challenges in migraine treatment and asked the Board to make Aimovig preferred.</p> <p data-bbox="596 982 1497 1154">Comment was offered by Jennifer Shear with Teva Pharmaceuticals providing information on Ajovy. Ms. Shear highlighted the indication, mechanism of action, dosing either monthly or quarterly, clinical trial data demonstrating efficacy over placebo and low adverse events and asked the Board to maintain Ajovy as preferred.</p> <p data-bbox="596 1198 1472 1365">Comment was offered by Laura Hill with Abbvie providing information on Ubrelvy. Ms. Hill asked Ubrelvy to be added as preferred adding Ubrelvy’s benefits include proven safety and efficacy compared to placebo, flexible dosing, tolerability profile similar to placebo, and can be used in patients with cardiovascular disease. Ms. Hill highlighted clinical trial data</p>	

Agenda Item	Record	Notes
	<p>demonstrating efficacy over placebo and is the only acute treatment with second-dose efficacy and asked the Board to add Ubrelvy as preferred.</p> <p>Comment was offered by Michael Sullivan, MD, Neurologist practicing in Minden, NV. Dr. Sullivan provided prescribing experience with Nurtec ODT, explaining it works well for his patients with minimal side effects and helps people return to normal function faster than with the triptan class. Dr. Sullivan stated Ubrelvy should be first-line acute treatment, especially for patients with significant cardiac histories.</p> <p>Comment was offered by Denis Patterson, DO, joined by Kristen Bowman, APRN, and Ross Jenson, MD, advocating for broader coverage of CGRP acute treatment options. Dr. Patterson highlighted his practice sees chronic pain and migraine sufferers leading to disability. Dr. Patterson stated his patients benefit from Ubrelvy and Nurtec ODT because they have fewer side effects than triptans and they can be used in patients with cardiovascular disease and recommends CGRPs are a good first-line treatment for acute migraine.</p> <p>Comment was offered by Rachael Gardner, APRN, advocating for more access to migraine treatments. Ms. Gardner highlighted the challenges with treating migraines with triptans due to side effects and reliance on opioids and barbiturates. Ms. Gardner offered her patient's experience with the CGRP has been positive with rapid pain freedom and few side effects and highlighted Nurtec ODT as beneficial since it can be taken without water, has few drug interactions, and can be used with comorbid conditions. Ms. Gardner asked for Nurtec ODT to be added as preferred.</p> <p>No further public comment was offered.</p>	
<p>ii. Drug class review presentation by OptumRx.</p>	<p>Dr. Jeffery displayed the list of medications within the class and highlighted the different indications, acute treatments, and preventative treatments. Dr. Jeffery reminded the Board there are prior authorization criteria on the medications in this class.</p>	

Agenda Item	Record	Notes
	Dr. Jeffery recommended the Board consider this class clinically and therapeutically equivalent.	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Board Member Adashek moved to accept the list as clinically and therapeutically equivalent. Deputy Attorney Lither stated no vote is necessary since the class was previously determined as clinically and therapeutically equivalent.	
iv. Presentation of recommendations for PDL inclusion by OptumRx.	Dr. Jeffery proposed no changes to the class.	

Agenda Item	Record	Notes
<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Board Member Adashek motioned to add Nurtec ODT to preferred and Board Member Chu seconded.</p> <p>Chairman Decerbo described the difficulty with classifying this class either by pharmacologic or therapeutic classification with the mix of prophylactic and abortive treatments. Chairman Decerbo asked the Board for feedback on reclassifying how these treatments are organized by preventative treatments and abortive treatments. Should Ubrelvy and Nurtec ODT be included with triptans?</p> <p>Board Member Adashek withdrew his motion to allow for discussion of reclassifying the agents.</p> <p>Deputy Attorney Lither stated the class could be split but it would need to be on a future agenda with that information and the Board can only address preferred and non-preferred status of medications today.</p> <p>Board Member Khurana agreed the acute treatment and preventative treatments are different aspects of the treatment of a patient with migraines.</p> <p>Board Member Chu asked if any of the preferred agents work off-label for abortive migraine treatment.</p> <p>Dr. Jeffery replied that neither Ajovy nor Emgality are used for abortive treatment. Dr. Jeffery detailed the direction given to classify these using Clinical Pharmacology, leading to the current CGRP class.</p> <p>Board Member Khurana moved to add Ubrelvy and Nurtec ODT as preferred since they are the only two abortive treatments in the class. Board Member Adashek seconded the motion.</p>	

Agenda Item	Record	Notes																																																								
	<p>Chairman Decerbo asked for the class to be added to a future agenda and separated into a migraine prevention class and a migraine abortive class. Chairman Decerbo referencing the motion and asked the Board if both Ubrelvy and Nurtec ODT need to be added as preferred.</p> <p>Board Member Adashek stated members could vote “no” on the motion and a new motion could be made if it does not pass.</p> <p>A vote was held:</p> <table border="0" data-bbox="590 558 1514 841"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> <p>Chairman Decerbo moved to add the migraine class on a future meeting agenda proposing an abortive class and prophylactic class. Board Member Adashek seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="590 1062 1514 1344"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																																							
Decerbo, Mark, Pharm.D. – Chair	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>																																																							
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																							
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																							
	Yes	No	Abst.																																																							
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																							
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																							
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																							
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																							
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																							
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																							

Agenda Item	Record	Notes																												
b. For Possible Action: Discussion and possible adoption of Ophthalmic Agents, Ophthalmics for Dry Eye Disease																														
i. Public comment	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was offered by Melissa Sommers with Novartis providing information on Xiidra for dry eye disease. Ms. Sommers highlighted the mechanism of action, indication for both the signs and symptoms of dry eye disease, included information that other treatment options do not address inflammation like Xiidra does. Ms. Sommers highlighted clinical data demonstrating Xiidra is safe and effective with few adverse events and is quickly effective. Ms. Sommers requested the Board add Xiidra as preferred.</p> <p>No further public comment was offered.</p>																													
ii. Drug class review presentation by OptumRx.	<p>Dr. Jeffery displayed the list of medications and their indications and recommended the Board consider the class clinically and therapeutically equivalent.</p>																													
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the list as clinically and therapeutically equivalent, Board Member Chu seconded the motion. A vote was held:</p> <table border="0" data-bbox="598 1128 1501 1404"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											

Agenda Item	Record	Notes																												
iv. Presentation of recommendations for PDL inclusion by OptumRx.	Dr. Jeffery displayed the current list of preferred medications without any recommended changes with Restasis and artificial tears remaining preferred.																													
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Chu moved to accept the list as presented without any changes, Board Member Ward seconded the motion. A vote was held:</p> <table border="0" data-bbox="590 521 1514 808"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
6. OptumRx Reports: New Drugs to Market and New Line Extensions	Dr. Jeffery highlighted new medications of interest for heart failure, Alzheimer’s disease, Multiple Sclerosis and highlighted some new generics due out soon including Amitiza, Fortical, Lyrica CR, Forteo, Zomig, and Humira not due until January 2023																													
7. Closing Discussion																														
a. Public comment on any subject	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p>																													
b. Date and Location of the next meeting.	Chairman Decerbo confirmed the next scheduled meeting will be March 25, 2021 and will be a virtual meeting.																													
i. Discussion of the next meeting																														
c. Adjournment	Chairman Decerbo adjourned the meeting at 3:25 p.m.																													
























Attachment A – Members of the Public in Attendance

Amy S Rodenburg
Andrew Gorzynski
Bailey Alan
Barbara Yaeger
Ben Droese, Amgen
Brandon Yip
Brent Fushimi
Carmen Oliver
Chelsea Leroue, Biohaven Pharmaceuticals
Chi Kohlhoff
Christa Cooper
David Large
Denis Patterson DO
Derek Ems, UCB
Deron Grothe
Douglas Britt
Elaine DeFelice

Jason Kniffin
Jeana Colabianchi
Jeanne Vander Zanden
Jenna M Gianninoto
Jennifer Gaynor
Jennifer Shear, Teva Pharmaceuticals
Joe Germain Jr.
Jonathan Wolin
Kaysen Bala
Kelvin Yamashita
Kevin Aholt RPh
Kimberly A. Flagg-Brown
Kristen Bowman APRN
Laura L Hill, Abbvie
Lori McDermott
Lovell R Robinson
Maninder Malik, SK Life Science

Matthew Bradley
Matthew Lennertz
Melissa Sommers, Novartis
Michael Sullivan MD
Michelle Duke
Natalie Cardenas
Nathan Smith
Quon Warner
Rachael Gardner
Ricafort Lawford
Robert Booth
Rodney Hamson, Epilepsy Foundation of Nevada
Ross Jenson MD
Steven Isaki
Susan Hertzberg
Tiffany N. Saunders-Newey

Attachment B – Submitted Written Comment

- | | | | | | | | |
|---|--|---|--|--|--|---|--|
| 
Fintepla
Medicaid_One_PageLancet_Lagae_2019 | 
Fintepla
ijamaneurology_nab52349 | 
Fintepla
AES BRIEF | 
Fintepla FINAL
PosSummary - S Kenned | 
Epidiolex Clinical
Testimony - S Kenne | 
Epidiolex - Written
Value Summary_Nev | 
Emgality_Medical
Value Summary_Nev | 
Emgality_Medical
Value Summary_Nev |
| 
Briviact Testimony -
D Ems - ADA.pdf | 
Ajoyv Letter - M
Agapova - ADA.pdf | 
Aimovig Clinical
Fact Sheet - B Drees | 
Ubrelyv Letter - S
Sharma - ADA.pdf | 
Ubrelyv Letter - M
Harb - ADA.pdf | 
Ubrelyv Letter - D
Patterson - ADA.pdf | 
Ubrelyv Letter -
Boulder Primary Care | 
Ubrelyv 2021 01
21.pdf |
| 
Nurtec ODT Nevada
Medicaid Support le | 
Nurtec ODT - Q
Nguyen - ADA.pdf | 
Nurtec
Letter_R_Gardner-ALLBEMD | 
Nurtec letter on
Nov 18_ADA | 
Fintepla-prescribin
g-information.pdf | 
Fintepla-medication-
guide.pdf | 
Fintepla.pdf | |